Compare BRZE & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRZE | VCEL |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2021 | 1996 |
| Metric | BRZE | VCEL |
|---|---|---|
| Price | $26.48 | $46.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 5 |
| Target Price | $37.88 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.2M | 704.3K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $738,182,000.00 | $276,259,000.00 |
| Revenue This Year | $22.69 | $19.40 |
| Revenue Next Year | $16.93 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 24.40 | 16.45 |
| 52 Week Low | $15.26 | $28.95 |
| 52 Week High | $37.33 | $48.75 |
| Indicator | BRZE | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 62.42 |
| Support Level | $26.02 | $32.47 |
| Resistance Level | $29.14 | N/A |
| Average True Range (ATR) | 1.27 | 1.81 |
| MACD | 0.42 | -0.21 |
| Stochastic Oscillator | 91.41 | 60.92 |
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates the majority of its revenue from the United States.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.